Cargando…
Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the co...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676496/ https://www.ncbi.nlm.nih.gov/pubmed/36419835 http://dx.doi.org/10.3389/fphys.2022.1028486 |
_version_ | 1784833609749757952 |
---|---|
author | Du, Lixin Qin, Jiao Wang, Dengchuan Zhao, Yunhui Xu, Ning Wu, Chaowen Yuan, Jianpeng |
author_facet | Du, Lixin Qin, Jiao Wang, Dengchuan Zhao, Yunhui Xu, Ning Wu, Chaowen Yuan, Jianpeng |
author_sort | Du, Lixin |
collection | PubMed |
description | Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the combination therapy of SGLT2i and GLP1RA will yield an additive benefit on cardiorenal endpoints. Lopez and colleagues recently did a cohort study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and aimed to address this issue. However, their findings are not consistent with those of previous studies. To confirm Lopez et al.’s findings (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and address the aforementioned inconsistencies, we conducted a meta-analysis based on relevant studies. Our meta-analysis identified that SGLT2i + GLP1RA combination therapy was significantly associated with the reduced risks of cardiovascular/cerebrovascular atherosclerotic, heart failure-associated, and death outcomes compared with SGLT2i/GLP1RA monotherapy. These might support this combination therapy used for better reducing cardiovascular and death events in T2D patients, especially in those with high or very high cardiovascular risk. This is a commentary on a previous article (Lopez et al.’s study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93)) published outside of Frontiers. Therefore, we submitted this manuscript as an Opinion article, as suggested in the Author Guidelines. |
format | Online Article Text |
id | pubmed-9676496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96764962022-11-22 Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients Du, Lixin Qin, Jiao Wang, Dengchuan Zhao, Yunhui Xu, Ning Wu, Chaowen Yuan, Jianpeng Front Physiol Physiology Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the combination therapy of SGLT2i and GLP1RA will yield an additive benefit on cardiorenal endpoints. Lopez and colleagues recently did a cohort study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and aimed to address this issue. However, their findings are not consistent with those of previous studies. To confirm Lopez et al.’s findings (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and address the aforementioned inconsistencies, we conducted a meta-analysis based on relevant studies. Our meta-analysis identified that SGLT2i + GLP1RA combination therapy was significantly associated with the reduced risks of cardiovascular/cerebrovascular atherosclerotic, heart failure-associated, and death outcomes compared with SGLT2i/GLP1RA monotherapy. These might support this combination therapy used for better reducing cardiovascular and death events in T2D patients, especially in those with high or very high cardiovascular risk. This is a commentary on a previous article (Lopez et al.’s study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93)) published outside of Frontiers. Therefore, we submitted this manuscript as an Opinion article, as suggested in the Author Guidelines. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676496/ /pubmed/36419835 http://dx.doi.org/10.3389/fphys.2022.1028486 Text en Copyright © 2022 Du, Qin, Wang, Zhao, Xu, Wu and Yuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Du, Lixin Qin, Jiao Wang, Dengchuan Zhao, Yunhui Xu, Ning Wu, Chaowen Yuan, Jianpeng Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title_full | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title_fullStr | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title_full_unstemmed | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title_short | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
title_sort | meta-analysis assessing the effectiveness of sglt2i+glp1ra combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676496/ https://www.ncbi.nlm.nih.gov/pubmed/36419835 http://dx.doi.org/10.3389/fphys.2022.1028486 |
work_keys_str_mv | AT dulixin metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT qinjiao metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT wangdengchuan metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT zhaoyunhui metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT xuning metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT wuchaowen metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients AT yuanjianpeng metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients |